Alnylam Pharmaceuticals (ALNY) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Alnylam Pharmaceuticals (ALNY) right now is Amvuttra ATTR-CM ramp: The March 2025 approval of Amvuttra for ATTR cardiomyopathy opened a market many multiples larger than its original polyneuropathy indication, and the launch is the single biggest growth driver. Net product revenue (FY2025) is ~$3.0B. If that keeps playing out, the setup is favourable; the risk to it is revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. No one can predict where ALNY trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Alnylam Pharmaceuticals (ALNY) higher?
1. Amvuttra ATTR-CM ramp
The March 2025 approval of Amvuttra for ATTR cardiomyopathy opened a market many multiples larger than its original polyneuropathy indication, and the launch is the single biggest growth driver. As a subcutaneous injection dosed once every three months, it offers a convenience angle versus daily oral therapies. Management's 2026 guidance of roughly $4.9 billion to $5.3 billion in net product revenue is built largely on this ramp continuing.
2. Crossing into sustained profitability
After years of heavy R&D spending, Alnylam reached GAAP and non-GAAP profitability in 2025 and posted roughly $206 million of net income in Q1 2026. This shift means revenue growth increasingly drops through to operating income rather than being consumed by burn. A self-funding commercial engine also reduces the historical risk of dilutive capital raises.
3. RNAi platform and pipeline optionality
Beyond TTR, Alnylam is advancing mivelsiran in Alzheimer's disease, ALN-6400 in a bleeding disorder, and other programs with data readouts expected across the year. Its RNAi delivery technology has already produced multiple approved drugs, giving the platform repeatability that early-stage biotechs lack. Novartis royalties on Leqvio add a growing, lower-risk revenue stream tied to the large cardiovascular market.
4. Global label and geographic expansion
The ATTR-CM indication has secured approvals beyond the US, including the European Commission, Japan, the UK, Brazil, and Canada. Each new geography adds addressable patients to the same commercial franchise without requiring a new drug. This international runway supports the multi-year growth trajectory embedded in analyst expectations.
What could weigh on ALNY?
Revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. The ATTR-CM market is now a genuine contest, with Pfizer's entrenched tafamidis (Vyndaqel/Vyndamax), BridgeBio's oral acoramidis (Attruby), and Ionis/AstraZeneca's eplontersen (Wainua) all competing. Biotech valuations are sensitive to clinical trial outcomes, and pipeline readouts in Alzheimer's and other areas could disappoint. The stock trades at a rich multiple of revenue that assumes years of strong growth, leaving room for sharp drawdowns on any stumble. Drug pricing pressure and patent or regulatory changes are ongoing overhangs for the sector.
Where ALNY trades today
A forecast starts from where the stock actually is. These are ALNY's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ALNY as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ALNY forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ALNY guide and whether ALNY is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ALNY outlook
The bottom line: what is driving Alnylam Pharmaceuticals (ALNY) is Amvuttra ATTR-CM ramp, with net product revenue (fy2025) at ~$3.0B. If that keeps playing out the setup is favourable; the risk is revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. No one can predict the price, so treat any ALNY forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ALNY with Walnut
Use Alnylam Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Alnylam Pharmaceuticals (ALNY)?
+
No one can reliably predict where ALNY will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Alnylam Pharmaceuticals higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ALNY higher?
+
The main growth drivers are Amvuttra ATTR-CM ramp; Crossing into sustained profitability; RNAi platform and pipeline optionality. Whether they play out is the real question, not a guaranteed path.
What are the risks to ALNY?
+
Revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. The ATTR-CM market is now a genuine contest, with Pfizer's entrenched tafamidis (Vyndaqel/Vyndamax), BridgeBio's oral acoramidis (Attruby), and Ionis/AstraZeneca's eplontersen (Wainua) all competing. Biotech valuations are sensitive to clinical trial outcomes, and pipeline readouts in Alzheimer's and other areas could disappoint. The stock trades at a rich multiple of revenue that assumes years of strong growth, leaving room for sharp drawdowns on any stumble. Drug pricing pressure and patent or regulatory changes are ongoing overhangs for the sector.
Will ALNY stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Alnylam Pharmaceuticals's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ALNY a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ALNY "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.